Assessment of ellagic acid action in 5-fluorouracil induced intestinal mucositis

Assessment of ellagic acid action in 5-fluorouracil induced intestinal mucositis

Authors

  • Dareen Al-hoshary Ministry of Health and Environments, Al -Kut Hospital, Al-Kut, Iraq
  • Munaf H. Zalzala Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq

DOI:

https://doi.org/10.31351/vol32issSuppl.pp33-41

Keywords:

ellagic acid, 5-FU, intestinal mucositis

Abstract

The intestinal mucositis define as inflammation and ulceration in the gastrointestinal tract wall and in some case in the oral cavity these cause by treatment with antineoplastic drug like 5-fluorouracil and Irinotecan and other types of chemotherapeutics drugs , 5-Fluorouracil-induced intestinal mucositis (IM) is consider as one of the more common tumor issue .it cause series of undesirables symptoms like severe diarrhea ,abdominal pain , stomach uncomfortable and other. The aim of this current study to see how ellagic acid act to  Attenuates 5-FU-Induced Intestinal Mucositis and  Diarrhea in Mice . we induced the intestinal mucositis by injected the mice intraperitoneally in 5-fluorouracil about 50mg per kg daily for four days respectively and then assessment the IM by measurement the level of some antioxidant enzymes like SOD , and level of some pro-inflammatory cytokines (IL-6) and lipid peroxidation biomarker (MDA) and we note the difference in the histopathological scoring after administration the ellagic acid to the mice in two different dose (10mg and 5mg per kg) daily for ten days respectively and before the fluorouracil injection  in one hour .pretreatment with ellagic acid specialized dose of 10mg per kg significant improvement in the level of antioxidant enzymes ,pro inflammatory cytokines ,lipid peroxidation biomarker and histopathologicaL score  compared with 5-FU group, moreover the potential action of ellagic acid was further supported by histopathological examination. all these data suggest that the ellagic acid effective in protective from 5-FU-induced intestinal mucositis.

References

Ali J, Khan AU, Shah FA, Ali H, Islam SU, Kim YS, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Vol. 239, Life Sciences. Elsevier Inc.; 2019. 116888 p.

Atiq A, Shal B, Naveed M, Khan A, Ali J, Zeeshan S, et al. Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents. Eur J Pharmacol. 2019;843(November 2018): 292– 306.

Araújo RS, de Barros ALB. Intestinal Mucositis Induced by Chemotherapy: an Overview. J Mol Pharm Org Process Res. 2015;03(03):18–9.

Brown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. J Oncol Pract. 2020;16(3):103–9.

Zhao L, Mehmood A, Soliman MM, Iftikhar A, Iftikhar M, Aboelenin SM, et al. Protective Effects of Ellagic Acid Against Alcoholic Liver Disease in Mice. Front Nutr. 2021;8(September):4–6.

Nejad KH, Sarkaki A, Dianat M, Farbood Y, Badavi M, Gharib-Naseri MK. Preventive effects of ellagic acid on nucleus tractus solitarius electrical activity and oxidative stress altered by cerebral global ischemia/reperfusion in rat. Brazilian Arch Biol Technol. 2017;60(December):1–11.

Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med. 2014;11(2):92–100.

Gawish SAAE, Nosseir DA, Omar NM, Sarhan NMR. Histological and ultra-structural study of 5-fluorouracil-induced small intestinal mucosal damage in rats. Asian J Cell Biol. 2013;8(1):1–21.

Zuccari G, Baldassari S, Ailuno G, Turrini F, Alfei S, Caviglioli G. Formulation strategies to improve oral bioavailability of ellagic acid. Appl Sci. 2020;10(10):1–27.

Dareen M. Al-hoshary, Munaf H. Zalzala. Mucoprotective effect of ellagic acid in 5 fluorouracil-induced intestinal mucositis model. Journal of Medicine and Life. 2023;16(5):712-718.

Zalzala M.H.; Al-Khfajy W.S.; Khaleel R.A. Cytotoxic Effect of 6-Ethyl-Chenodeoxycholic Acid and Cabazitaxel on PC-3 Cells. Drug Development and Registration. 2023; 12(1):52-58

Downloads

Published

2023-11-01